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Introduction
Breath contains hundreds of  volatile organic 
compounds (VOCs), the composition of which 
is altered in a wide variety of diseases [1]. The 
biochemical mechanisms that lead to the formation 
of breath VOCs remain largely hypothetical [2–6]. 
Although a mechanistic understanding of VOC origin 
is not required to use VOCs in the exhaled breath as a 
diagnostic tool [1], it would enable identification of the 
most appropriate patient populations to target with the 
test and would facilitate the acceptance of breath tests 
by clinicians.
Bacteria have been implicated in the production 
of VOCs for a long period of time. For centuries, lung 
abscesses have been reported to have a strong odor; 
breath odors were described as a diagnostic test in the 
ancient writings of Hippocrates. VOC profiles can dis­
tinguish between particular pathogens in vitro and in 
animal models of pneumonia [7–9]. This suggests that 
bacteria create the volatile compounds responsible for 
the odor associated with infection [10], and that par­
ticular bacterial species produce characteristic VOC 
profiles.
Recent developments in genomics allow for unbi­
ased assessment of bacteria present in clinical samples 
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Abstract
Breath contains hundreds of volatile organic compounds (VOCs), the composition of which is 
altered in a wide variety of diseases. Bacteria are implicated in the formation of VOCs, but the 
biochemical mechanisms that lead to the formation of breath VOCs remain largely hypothetical. We 
hypothesized that bacterial DNA fragments in sputum of CF patients could be sequenced to identify 
whether the bacteria present were capable of producing VOCs found in the breath of these patients.
Breath from seven patients with cystic fibrosis was sampled and analyzed by gas­chromatography 
and mass­spectrometry. Sputum samples were also collected and microbial DNA was isolated. 
Metagenomic sequencing was performed and the DNA fragments were compared to a reference 
database with genes that are linked to the metabolism of acetaldehyde, ethanol and methanol in the 
KEGG database.
Bacteria in the genera Escherichia, Lactococcus, Pseudomonas, Rothia and Streptococcus were 
found to have the genetic potential to produce acetaldehyde and ethanol. Only DNA sequences 
from Lactococcus were implicated in the formation of acetaldehyde from acetate through aldehyde 
dehydrogenase family 9 member A1 (K00149). Escherichia was found to be genetically capable of 
producing ethanol in all patients, whilst there was considerable heterogeneity between patients 
for the other genera. The ethanol concentration in breath positively correlated with the amount of 
Escherichia found in sputum (Spearman rho  =  0.85,  P  =  0.015). Rothia showed the most versatile 
genetic potential for producing methanol.
To conclude, bacterial DNA fragments in sputum of CF patients can be linked to enzymes 
implicated in the production of ethanol, acetaldehyde and methanol, which are VOCs that are 
predictive of respiratory tract colonization and/or infection. This supports that the lung microbiome 
can produce VOCs directly.
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through direct sequencing of DNA in each sample 
[11]. The corresponding gene function and taxonomic 
origin can be predicted by comparing the sequenced 
DNA fragments to a reference database containing 
sequences of known taxonomy and/or function [12]. 
This ‘metagenomic’ approach has been especially use­
ful for characterizing the polymicrobial communities 
that exist in human­associated environments, e.g. lungs 
of individuals with cystic fibrosis (CF), where there is 
a high abundance of different types of bacteria due to 
decreased mucociliary clearance [13].
In a related study, 2,3­butanedione was implicated 
as a marker for microbial fermentation processes in the 
lungs [12]. In this study, we focused on the presence and 
quantification of ethanol, acetaldehyde and methanol 
in breath from CF patients. Ethanol and acetaldehyde 
were described as an important marker of positive spu­
tum and broncho­alveolar lavage fluid cultures with 
any bacterium in several studies [19–21], and they are 
found in the breath of healthy people [22]. Ethanol and 
acetaldehyde were both described as general markers 
of bacterial growth in a systematic review of all in vitro 
studies [9]. Methanol is found in the breath of healthy 
people [23], and could have microbial or human ori­
gins. Methanol has been shown to regulate the produc­
tion of detoxification genes in mice [24].
We hypothesized that bacterial DNA fragments in 
sputum of CF patients could be sequenced to identify 
whether the bacteria present were capable of produc­
ing VOCs found in the breath of these patients. For 
this purpose, we used gas­chromatography and mass­
spectrometry to detect VOCs in breath and genomics 
and metagenomics to characterize bacterial genes in 
sputum.
Methods
Inclusion and obtained samples
This was an observational cohort study that included 
7 patients with CF recruited at the University of 
California San Diego Adult CF clinic as described in 
previous studies [12, 14]. IRB approval was obtained 
from the University of California Institutional Review 
Board (HRPP 081500) and San Diego State University 
Institutional Review Board (SDSU IRB#2121). After 
informed consent was obtained we collected sputum 
and breath samples. Species identification (with 16S) 
and per species genetic potential (with metagenomic 
shotgun analysis) were studied on sputum samples. The 
16S data have been published previously, along with 
some of the metagenomic data [12, 15, 16].
Breath analysis
From each CF patient and a healthy volunteer (in the 
same room), three breath samples were collected within 
5 min of each other. Volunteers were instructed to eat 
and drink normally until 1 h before sample collection; 
food and drink in the hours before sampling were 
recorded. Prior to sample collection, volunteers used 
saline to rinse their mouths, and volunteers were 
instructed to discard the first third of their breath 
(approximately 2 s), collecting the last two­thirds 
of the breath sample which is less influenced by the 
contents of the oral cavity. Samples were collected 
in 1.9L stainless steel canisters [17], along with a 
simultaneous background room air sample. Sample 
collection and analysis is described in Whiteson [12], 
using the approach detailed in Colman [18]. Briefly, 
breath samples were concentrated in a stainless steel 
loop submerged in liquid nitrogen, and then heated 
to ~80 C and split into six different columns. The data 
shown here were obtained from the DB­5 ms column 
(J&W; 60 m, 0.25 mm I.D., 0.5 mm film thickness) 
output to a quadrupole mass selective detector (MSD, 
HP5973). The absolute intensity information is not the 
major objective of the results shown here, but rather 
the relative amounts of the VOCs of interest in relation 
to the microbial sequence information obtained from 
parallel samples.
KEGG
The KEGG compound database was searched for 
ethanol (C00469), acetaldehyde (C00084) and 
methanol (C00132). The enzyme numbers (ec:x.x.x.x) 
associated with these compounds were extracted and 
coupled to the orthology database (K­numbers). For 
each of these K­numbers, the corresponding gene 
sequences in bacterial species that were previously 
described in the CF respiratory tract were extracted and 
then used to create a database.
16S rDNA analysis
The 16S rRNA gene amplicon data from these samples 
have been published, along with the associated 
methods [15]. Briefly, frozen sputum samples were 
thawed in the presence of Trizol reagent, DNA was 
extracted using a Life Technologies protocol, and 
amplicon sequencing of the V4 region (515F/860R) 
of the bacterial 16S rRNA gene was carried out at the 
RTSF Genomics Core at Michigan State University 
using the MiSeq v2 reagent kit for paired­end 250bp 
sequencing. Sequence data quality control with 
Prinseq [25] and a Mothur SOP for Miseq data [26] 
were employed to obtain 97% operational taxonimic 
units (OTUs), a proxy for bacterial species. Data 
processing and OTU clustering are described in 
further detail in Quinn et al [15].
Metagenomic analysis
Fresh sputum samples were processed using hypotonic 
lysis and washing to remove eukaryotic cells, damaged 
bacterial cells and extracellular DNA, as described 
previously [12, 14, 27]. Ion Torrent sequencing yielded 
19.8 million reads, and 13.6 million reads were retained 
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after removal of low quality reads or human sequences 
[25, 28]. Some of these data were presented in previous 
publications that did not focus on breath analysis 
[15]. These metagenomic data were then compared to 
the previously constructed database (using BLASTn 
searches) to assist with assigning function to these 
data from CF patients. Metagenomic sequences 
were selected if they matched ethanol, acetaldehyde 
or methanol pathway genes from the KEGG with a 
minimum length of 40 bp, sequence identity of 40% 
and a BLAST e­value cutoff of 1  ×  10−10.
Data analysis
The number of sequences in metagenomic data from 
CF patients that matched sequences in the database 
was calculated per patient (normalized to the number 
of sequence reads for that sample), per microbe (on the 
genus level) and per orthological unit (K­number from 
KEGG database). Heatmaps were constructed using 
the ggplot2 package within the R environment via the 
R­studio interface [29].
Results
Patients
Seven patients with CF were included from the UCSD 
Adult CF Clinic. Their ages ranged from 27 to 52 years. 
All patients were on chronic antibiotic therapy. Three 
patients received additional antibiotics in the week 
prior to sampling. The predominant microorganism 
cultured in the clinical microbiology lab did not often 
reflect the dominant microbe in the sequence data 
[12, 15, 30].
Acetaldehyde
Acetaldehyde was present in the breath of all included 
patients. Figure 1 shows the enzymes that are involved 
in the metabolism of acetaldehyde. The enzymes that 
convert between acetate and acetaldehyde, and between 
ethanol and acetaldehyde are bi­directional. Bacteria 
in the genera Escherichia, Lactococcus, Pseudomonas, 
Rothia and Streptococcus were found to have the genetic 
potential to produce acetaldehyde (figure 2). Only 
DNA sequences from Lactococcus were implicated in 
the formation of acetaldehyde from acetate through 
aldehyde dehydrogenase family 9 member A1 (K00149). 
Most reads associated with threonine aldolase were 
associated with Rothia.
Ethanol
Ethanol was also present in the breath of all patients. 
Figure 1 also shows the enzymes that are associated with 
ethanol. Since ethanol is synthesized from acetaldehyde 
(and vice versa), most enzymes are similar to those 
described in the section on acetaldehyde. Escherichia, 
Pseudomonas, Rothia and Streptococcus were found to 
have the genetic potential to produce ethanol (figure 3). 
Escherichia was found to be genetically capable of 
producing ethanol in all patients, whilst there was 
considerable heterogeneity between patients for the 
other genera. The ethanol concentration in breath 
positively correlated with the amount of 16S rRNA 
Figure 1. Schematic representation of acetaldehyde and ethanol production. Name: abbreviated enzyme name, as given by KEGG. 
K: orthological number given by the KEGG database. Bold: genetic sequences of these enzymes are found in the sputum of CF 
patients.
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Figure 2. Genetic capabilities for ethanol production by 
different bacteria in the sputum samples of CF patients. 
Heatmaps of VOC concentrations and DNA fragment 
abundance. The intensity of blue represents the relative 
concentration/abundance. Upper panel: ethanol 
concentration in breath. Middle panel: relative abundance 
of Streptococcus species, Escherichia species, Rothia species 
and Pseudomonas species. Lower panel: number of DNA 
fragment copies per microbe, per enzyme (see figure 1), 
normalized to the number of reads for that sample.
Figure 3. Genetic capabilities for acetaldehyde production 
by different bacteria in the sputum samples of CF patients. 
Heatmaps of VOC concentrations and DNA fragment 
abundance. The intensity of blue represents the relative 
concentration/abundance. Upper panel: acetaldehyde 
concentration in breath. Middle panel: relative abundance 
of Streptococcus species, Escherichia species, Rothia species 
and Pseudomonas species. Lower panel: number of DNA 
fragment copies per microbe, per enzyme (see figure 1), 
normalized to the number of reads for that sample.
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copies of Escherichia found in sputum (Spearman 
rho  =  0.85, P  =  0.015).
Methanol
Figure 4 displays the enzymes that are linked to the 
production of methanol in the KEGG database for 
which matching sequences were found in the CF sputum 
samples. Rothia showed the most versatile genetic 
potential for producing methanol. DNA sequences that 
matched to Pseudomonas, Streptococcus and Escherichia 
were also linked to methanol production (figure 5).
Discussion
The reported data support the hypothesis that bacterial 
DNA fragments in sputum of CF patients can be 
linked to gene functionality that would result in the 
production of VOCs that were also found in the breath 
of these patients. We found that the microbes present 
in these samples have the potential to produce ethanol, 
acetaldehyde and methanol, three VOCs that have 
been previously linked with airway colonization and 
pneumonia [19–21]. As a breath research community 
we should look at the pulmonary microbiome as a 
potential source for the VOCs we find in exhaled breath.
To our best knowledge, this is the second study to 
link VOCs in exhaled breath with their microbial pro­
ducers via metagenomic analysis of the airway microbi­
ome. In an earlier study drawing from the same  samples, 
2,3­butanedione in breath was linked to anaerobic 
metabolism of Streptococcus spp., Rothia mucilaginosa, 
and other acetoin metabolizers. 2,3­butanedione was 
more abundant during exacerbation, and decreased 
dramatically after antibiotic treatment; it may be a use­
ful marker of exacerbation and of successful treatment 
in patients with CF [12]. This study further extends 
those findings to include other VOCs that have been 
studied more widely as markers of bacterial coloniza­
tion and infection of the respiratory tract. The role of 
microbes in the production of these compounds is not 
new; it has been studied particularly well in the gut and 
in biogas systems [31, 32]. Excess production of etha­
nol by dysbiosis of the microbiome in the gut is even 
recognized as a clinical syndrome called auto­brewery 
syndrome, which is highly disabling as patients are con­
stantly intoxicated [33]. Local acetaldehyde production 
by bacteria in the gut has been implicated in the patho­
genesis of colon carcinoma [34]. However, no research 
has been performed on the potential harmful effects of 
ethanol and acetaldehyde locally in the lung.
This study has several limitations. First, we focused 
only on three VOCs; acetaldehyde, ethanol and metha­
nol, as a lot is known about their metabolism and there­
fore we could obtain gene sequences from the bacteria 
in the respiratory microbiome. These VOCs are of great 
interest as they are implicated as markers of coloniza­
tion and/or infection of the respiratory tract [19–21]. 
However, other markers may be just as, or even more, 
clinically relevant to study in the future. For that, more 
knowledge on the metabolic pathways leading to these 
markers is required. There are also likely to be other, 
unknown, metabolic pathways that lead to the produc­
tion of acetaldehyde, ethanol and methanol that are 
currently not listed in the KEGG database.
Another limitation is our use of breath and sputum 
from seven patients with CF. The generalizability of 
the results has to be tested in patients with other res­
piratory diseases and the validity has to be replicated 
in larger cohorts of patients. With increasing numbers 
of included patients, more quantitative analyses might 
be possible. Furthermore, we focused on bacterial pro­
duction of VOCs. We cannot exclude that fungi are also 
Figure 4. Schematic representation of microbial methanol production. Name: abbreviated enzyme name, as given by KEGG. K: 
orthological number given by the KEGG database. Bold: genetic sequences of these enzymes are found in the sputum of CF patients.
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capable of producing the studied metabolites. Indeed, it 
is suggested in the literature that ethanol and acetalde­
hyde is produced in vitro by Candida albicans [35–38]. 
We have also not studied the influence of substrates for 
the production of ethanol, methanol and acetaldehyde. 
Ingested ethanol is an obvious source; but this bias was 
excluded as the subjects did not drink alcohol around 
sample collection. However, non­alcohol beverages 
may also contribute [39].
The strengths of these studies are the prospective 
data collection and the meticulous analysis of the sam­
ples. The metagenomic analysis of the in tact bacterial 
DNA allowed for a comprehensive view on the pathways 
that are involved in the production of the VOCs. Further­
more, while sequencing DNA from a sputum sample in 
itself does not support the viability of the bacteria iden­
tified, as the DNA could be extracellular or come from 
dead cells, most bacteria identified in the metagenomes 
from the same samples were found to be viable in a capil­
lary culture model, supporting the possibility that they 
are capable of producing the VOCs identified here [16].
While Rothia and Streptococcus may be converting 
ethanol to acetaldehyde, the presented data suggest that 
Lactococcus, from the order of Lactobacilales and a close 
cousin to Streptococcus, was the only bacterium in the 
lung of CF patients that contains annotated genes to 
metabolize acetaldehyde from acetate, and vice versa. 
Acetaldehyde leads to a pro­inflammatory, oxidative 
stress and carcinogenic response. The conversion to 
acetate protects against this [32, 40]. Acetate is a short 
chain fatty acid whose production from mucins by oral 
anaerobes may enable Pseudomonas to derive nutrients 
from mucins that it otherwise cannot access [47]. Lacto­
coccus is also part of the healthy, normal oral and airways 
microbiome; the conversion of a toxic molecule (acetal­
dehyde) to an anti­inflammatory short chain fatty acid 
(acetate) could be an important role, complicated by 
the fact that acetate is a nutrient for Pseudomonas. The 
fact that volatile molecules produced throughout the 
airways and oropharyngeal cavity can travel means that 
they can impact the physiology of host and bacterial 
cells throughout the airways, even coordinating physi­
ological events the way that hormones do in multicel­
lular organisms, with interesting implications for both 
microbiology and human health.
An important caveat to determining the origin of 
a particular VOC found in breath is that many mole­
cules can be produced by humans or bacteria, therefore 
it is not possible to determine whether the molecule 
has human or bacterial origin. Furthermore, bacterial 
physiology is heavily influenced by interactions with 
the host immune system [41]. For example, Pseudo­
monas and some other anaerobes can use nitrate as an 
alternative electron acceptor [42], and inflammation 
results in the recruitment of immune cells that produce 
nitrate [43–45]. In addition, neutrophils are thought 
to consume a large fraction of the oxygen available in 
the CF lung [46], forcing the colonizing microbes to 
rely on fermentation or anaerobic respiration, which 
is likely to be a large part of why growth rates in the 
CF lung are very slow—Staphylococcus aureus doubling 
times are slow and heterogeneous, averaging about two 
weeks in a recent study using the incorporation of stable 
isotope labels into bacteria isolated from CF sputum 
samples [18]. VOC production profiles of slow growing 
microbes is likely to differ from typical culture condi­
tions, and emphasizes the importance of considering 
Figure 5. Genetic capabilities for methanol production 
by different bacteria in the sputum samples of CF patients. 
Heatmaps of VOC concentrations and DNA fragment 
abundance. The intensity of blue represents the relative 
concentration/abundance. Upper panel: methanol 
concentration in breath. Middle panel: relative abundance 
of Streptococcus species, Escherichia species, Rothia species 
and Pseudomonas species. Lower panel: number of DNA 
fragment copies per microbe, per enzyme (see figure 4), 
normalized to the number of reads for that sample.
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physiologically relevant conditions and combining in 
vitro and in vivo approaches.
To conclude, bacterial DNA fragments in sputum 
of CF patients can be linked to enzymes implicated in 
the production of ethanol, acetaldehyde and methanol, 
which are VOCs that are predictive of respiratory tract 
colonization and/or infection. This confirms that the 
lung microbiome can produce VOCs directly.
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